Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Oregon Health and Science University
Summary
This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).
Eligibility
- Age range
- 18–90 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Documented history of oHCM with documented resting and/or Valsalva LVOT obstruction ≥ 50 mmHg who are currently receiving mavacamten commercially. * Echo-derived LVEF ≥55% on mavacamten at the time of enrollment. * Patient willing to consent for the study and undergo the study procedures. Exclusion Criteria: * Severe aortic stenosis or sub-aortic obstruction * Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM (eg, Noonan syndrome, Fabry disease, amyloidosis). * History of LVEF \<30%. * Paroxysmal atrial fibrillation (AF) with documented…
Interventions
- DrugAficamten
Patients will be switched from mavacamten to aficamten. Mavacamten will be stopped at enrollment, and aficamten started 2 weeks later.
Locations (2)
- St. Luke's Hospital - Mid America Heart InstituteKansas City, Missouri
- Oregon Health & Science UniversityPortland, Oregon